logo

Omeros Corp. (OMER)



Trade OMER now with
  Date
  Headline
12/5/2019 9:33:46 AM Omeros Prices Public Offering Of $50.0 Mln In Shares At $13.10 Per Share
12/4/2019 7:04:42 AM Omeros Reports Positive Data In Pivotal Trial Of HSCT-TMA Patients Treated With Narsoplimab
11/4/2019 7:53:52 AM Omeros Announces Publication Of Study Results On Impact Of OMIDRIA On Opioid Use And Pain
10/28/2019 8:51:02 AM Omeros Initiates BLA Submission For Narsoplimab For Treatment Of HSCT-TMA
7/31/2019 8:36:40 AM Omeros, Lonza Announce Long-term Manufacturing Agreement For Narsoplimab
7/31/2019 8:34:21 AM Omeros And Lonza Enter Long-Term Manufacturing Agreement For Commercial Supply Of Narsoplimab
7/15/2019 6:17:18 AM Wedbush Reiterates Omeros Corp. (OMER) At Neutral With $18 Price Target
5/20/2019 10:05:44 AM Wedbush Is Lowering Omeros Corp. (OMER) FY19 Rev. Estimate To 96.7 M From 97.2 M
5/20/2019 10:05:20 AM Wedbush Is Cutting Omeros Corp. (OMER) FY20 Estimate To -2.13 From -0.96
5/20/2019 10:05:06 AM Wedbush Is Lowering Omeros Corp. (OMER) Q4 20 Estimate To -0.83 From -0.52
5/20/2019 10:04:51 AM Wedbush Is Cutting Omeros Corp. (OMER) Q3 20 Estimate To -0.44 From -0.14
5/20/2019 10:04:40 AM Wedbush Is Cutting Omeros Corp. (OMER) Q2 20 Estimate To -0.43 From -0.15
5/20/2019 10:04:29 AM Wedbush Is Lowering Omeros Corp. (OMER) Q1 20 Estimate To -0.43 From -0.16
5/20/2019 10:04:06 AM Wedbush Is Lowering Omeros Corp. (OMER) FY19 Estimate To -1.84 From -0.78
5/20/2019 9:54:58 AM Wedbush Is Lowering Omeros Corp. (OMER) Q4 19 Estimate To -0.43 From -0.16
5/20/2019 9:54:45 AM Wedbush Is Cutting Omeros Corp. (OMER) Q3 19 Estimate To -0.45 From -0.19
5/20/2019 9:54:28 AM Wedbush Is Cutting Omeros Corp. (OMER) Q2 19 Estimate To -0.47 From -0.21
5/20/2019 9:53:54 AM Wedbush Reiterates Omeros Corp. (OMER) At Neutral With $18 Up From $17 Price Target
3/1/2019 7:37:35 AM Omeros Q4 Net Loss $23.5 Mln Or $0.48/Shr Vs Loss $16.6 Mln Or $0.34/Shr Last Year
  
 
>